Materials and Methods: The study was designed as prospective, single arm, multicenter registry study with target number of patients of 200. The primary endpoint of the study was 6-month tumor response assessed by mRECIST. The inclusion criteria of the study included: single nodular or multinodular HCCs, measurable lesion Z 1 cm, no evidence of vascular, biliary invasion or distant metastasis, performance status 0 or 1, Child-Pugh score 5-7. Review of medical records were performed to find any adverse event following the treatment. The study protocol was terminated when a patient had progression of disease, had additional treatment other than DEB-TACE, was lost to follow-up, was transferred to other institute or expired. Results: The patients were enrolled in the study between May 2011 and April 2013. On central review, 48 patients were excluded from analysis and 152 patients (M:F¼125:27, mean age 61) remained. Child-pugh class was dominantly A (143/ 152, 94.1%). The tumor was single nodular in 84 (55.3%) and BCLC stage was O in 15 (9.9%), A in 103 (67.8%) and B in 34 (22.4%). After first DEB-TACE procedure, 111 (73.0%) of the patients suffered from post-embolization syndrome (PES), and there was serious adverse event (SAE) in 8 (5.3%). Total 73 sessions of additional treatment was performed in 59 patients (38.8%). There were 2 patients with SAE after additional treatments. There was 51 (33.6%) patients with bile duct injury confirmed by follow-up imaging. According to mRECIST, 1month response was CR in 64 (42.1%), PR in 77 (50.6%), SD in 8 (5.3%) and PD in 3 (2.0%) patients. Before 6-month followup, the protocol was terminated in 45 (29.6%) patients. Total 120 patients (including patients with protocol termination with PD) were eligible for 6-month response evaluation, and the response was CR in 55 (45.8%), PR in 13 (10.8%) and SD in 2 (2.0%) and PD in 50 (41.7%). There was 2 mortality until 6month follow up.
Conclusion:In nodular HCC, DEB-TACE had 92.7% 1month and 56.6% 6-month response rate. PES and bile duct injury was common, and there were 2 cases with mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.